Buy & Sell iShares MSCI Japan ETF (EWJ) – iShares MSCI Japan ETF Price Today
Aura AI Summary
Key Stats
- -Market Cap
- Broad Market / FactorSector
- -5.14%3M Drawdown
- -Enterprise Value
- -Dividend Yield
- 43% Buy | 57% SellTrading Activity
- 19 daysTypical Hold Time
Over the past 52 weeks, iShares MSCI Japan ETF has traded between a low of $71.69 and a high of $96.33, highlighting its annual price range. Over the past three months, iShares MSCI Japan ETF has recorded a drawdown of -5.14%, reflecting recent price volatility. On average, investors hold iShares MSCI Japan ETF for approximately 19 days, indicating typical investor behavior on the platform.
About iShares MSCI Japan ETF
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Most Recent News
Over 100 drugs in clinical trials aim to transform age-related macular degeneration treatment by 2026
DelveInsight's 2026 report reveals more than 100 drugs in development for age-related macular degeneration (AMD), involving over 90 companies globally. These therapies include novel mechanisms like gene therapy, mitochondrial stabilization, and VEGF ...

Cell and gene therapy CDMO market set to grow at 24% CAGR, reaching $57.1B by 2034.
The cell and gene therapy contract development and manufacturing organization (CDMO) market is projected to grow at a compound annual growth rate (CAGR) of approximately 24% from 2026 to 2034, reaching a market size of $57.1 billion by 2034. Growth i...

Polymeric biomaterials market to hit $267B by 2034, driven by regenerative medicine and healthcare growth.
The global polymeric biomaterials market, valued at $69.55 billion in 2024, is projected to grow at a CAGR of 15.86% to reach $267.25 billion by 2034. Growth is fueled by increasing demand in regenerative medicine, orthopedics, and wound care, with A...
